Cardiovascular Drugs
•32 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (32)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly's incretin franchise targets cardiovascular/metabolic health; aligns with Cardiovascular Drugs.
|
$816.66B |
$863.11
+2.20%
|
|
NVO
Novo Nordisk A/S
Wegovy and Ozempic offer cardiovascular risk reduction benefits, aligning with the cardiovascular drugs investable theme.
|
$223.06B |
$49.45
-1.19%
|
|
MRK
Merck & Co., Inc.
Winrevair signals a cardiovascular drug development effort within Merck's diversified portfolio.
|
$215.90B |
$85.99
-0.34%
|
|
AMGN
Amgen Inc.
Repatha is a cardiovascular drug addressing LDL-C reduction.
|
$160.47B |
$298.45
+2.21%
|
|
PFE
Pfizer Inc.
Cardiovascular drugs (e.g., Eliquis) are a core, sizable portion of Pfizer's therapeutic offerings.
|
$140.14B |
$24.66
+1.50%
|
|
BMY
Bristol-Myers Squibb Company
Camzyos and related cardiology assets place Cardiovascular Drugs as a direct segment.
|
$93.77B |
$46.11
+1.07%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Factor XI antibodies represent cardiovascular/thrombosis therapy development.
|
$69.08B |
$651.52
-0.39%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$20.15B |
$445.96
-1.67%
|
|
ROIV
Roivant Sciences Ltd.
Mosliciguat is an inhaled sGC activator for PH-ILD, aligning with Cardiovascular Drugs.
|
$13.59B |
$19.98
+2.07%
|
|
VTRS
Viatris Inc.
Portfolio includes cardiovascular drugs and related assets (selatogrel, potential CV indications).
|
$12.16B |
$10.36
|
|
BBIO
BridgeBio Pharma, Inc.
Attruby's cardiovascular indication places BridgeBio in the cardiovascular drug space.
|
$11.97B |
$62.65
-1.14%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.59B |
$63.55
+2.09%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Plozasiran targets triglyceride-rich lipoproteins with cardiometabolic indications, aligning with Cardiovascular Drugs.
|
$5.85B |
$42.40
+0.20%
|
|
NAMS
NewAmsterdam Pharma Company N.V.
Obicetrapib targets LDL-C and Lp(a) reductions in cardiovascular disease, classifying it under 'Cardiovascular Drugs'.
|
$3.51B |
$37.92
-2.07%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
ARCALyst targets cardiovascular inflammatory disease (recurrent pericarditis), aligning with the cardiovascular drug category.
|
$2.74B |
$36.98
-0.83%
|
|
MLYS
Mineralys Therapeutics, Inc.
The company is pursuing a cardiovascular hypertension therapy, placing Mineralys under the Cardiovascular Drugs category.
|
$2.66B |
$40.84
-0.68%
|
|
EWTX
Edgewise Therapeutics, Inc.
EDG-7500 targets hypertrophic cardiomyopathy, placing Edgewise in the cardiovascular drugs space.
|
$1.92B |
$18.28
-2.09%
|
|
MAZE
Maze Therapeutics, Inc.
Maze targets cardiovascular and renal/metabolic diseases with its precision medicine approach and lead programs.
|
$1.44B |
$33.00
-0.66%
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$588.65M |
$2.96
+4.40%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Sotagliflozin and INPEFA target heart failure and hypertrophic cardiomyopathy, placing Lexicon in the cardiovascular drug space.
|
$501.19M |
$1.39
+3.36%
|
|
AMRN
Amarin Corporation plc
Amarin's flagship product VASCEPA/icosapent ethyl is a cardiovascular drug indicated to reduce major adverse cardiovascular events when added to statin therapy, making 'Cardiovascular Drugs' a core category.
|
$335.03M |
$16.27
-0.82%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199's mechanism targets vascular function and cerebral perfusion, aligning with cardiovascular drug themes.
|
$302.76M |
$7.05
+0.71%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
TNYA
Tenaya Therapeutics, Inc.
The company targets cardiovascular conditions (heart failure/cardiomyopathies) through its therapeutic programs.
|
$234.24M |
$1.46
+15.87%
|
|
APLT
Applied Therapeutics, Inc.
Out-licensing of AT-001 for Diabetic Cardiomyopathy indicates a cardiovascular indication program.
|
$162.81M |
$1.15
+1.77%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$102.65M |
$1.93
+2.39%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$79.32M |
$1.12
+2.27%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Ifetroban targets cardiovascular conditions (DMD cardiomyopathy), placing it under cardiovascular drug therapeutics.
|
$44.73M |
$2.99
-6.85%
|
|
VERU
Veru Inc.
Sabizabulin is being developed for atherosclerotic cardiovascular disease, placing Veru in the cardiovascular drug space.
|
$43.24M |
$2.96
-1.50%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$30.45M |
$7.29
-2.48%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal focuses on a cardiovascular anticoagulant, placing it in the Cardiology Drugs category.
|
$26.87M |
$12.89
-0.23%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$10.18M |
$0.78
+1.15%
|
Loading company comparison...
Loading industry trends...
Loading research report...
